
Pulmonary Hypertension
On this page
Pulmonary hypertension (high blood pressure in the lungs) is a rare and serious blood vessel disorder of the lungs, affecting one or two people in a million.
The UCSF Pulmonary Hypertension Program offers evaluation, diagnosis and treatment of primary pulmonary hypertension (PPH) and secondary pulmonary hypertension, which is often misdiagnosed. The secondary type is a side effect of another condition, such as emphysema or lupus, while PPH is not.
We are one of only three centers on the West Coast designated a comprehensive center of care by the Pulmonary Hypertension Association. This recognition is given to programs that demonstrate superior ability to care for patients with this complex condition and are making important contributions to research.
Pulmonary hypertension (high blood pressure in the lungs) is a rare and serious blood vessel disorder of the lungs, affecting one or two people in a million.
The UCSF Pulmonary Hypertension Program offers evaluation, diagnosis and treatment of primary pulmonary hypertension (PPH) and secondary pulmonary hypertension, which is often misdiagnosed. The secondary type is a side effect of another condition, such as emphysema or lupus, while PPH is not.
We are one of only three centers on the West Coast designated a comprehensive center of care by the Pulmonary Hypertension Association. This recognition is given to programs that demonstrate superior ability to care for patients with this complex condition and are making important contributions to research.
Locations
Providers
Awards & recognition

Best in the West and No. 3 in the nation for pulmonology & lung surgery

One of the nation's best for heart & vascular care

Accredited center of comprehensive care (Pulmonary Hypertension Association)
Related services
Related conditions & treatments
Conditions
Clinical trials
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)Opens in a new window
Recruiting
Percentage of Treatment group patients experiencing any device-related Major Adverse Cardiovascular or Neurological Events (MACNE) during the first 90-days…Pulmonary Hypertension Association RegistryOpens in a new window
Recruiting
PAH guideline-recommended diagnostics assessed include chest radiography, echocardiogram, ventilation-perfusion (V/Q) scan, pulmonary function tests,…Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)Opens in a new window
Recruiting
Ctrough was the lowest concentration of Sotatercept in serum just before the next dose. Blood samples will be collected at multiple time points to estimate…






